{"id":389145,"date":"2023-10-29T00:00:00","date_gmt":"2023-10-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0007-2023-biopharma-epilepsy-disease-landscape-forecast-g7-2023\/"},"modified":"2026-04-27T23:24:34","modified_gmt":"2026-04-27T23:24:34","slug":"dlsfcg0007-2023-biopharma-epilepsy-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0007-2023-biopharma-epilepsy-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Epilepsy | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>Epilepsy, which afflicts approximately 4.7 million people in the major markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient\u2019s seizure syndrome and seizure type. The market is heavily genericized, and most of the anti-epileptic drugs (AEDs) can be used as monotherapies or in combination. However, recent entrants like cenobamate, fenfluramine, and ganaxolone are carving share in the market, despite being high-priced branded products, by targeting underserved and orphan epilepsy populations. This report provides a detailed account of dynamics in this complex market, including the continued dominance of second-generation AEDs while emerging therapies nevertheless gain traction by addressing unmet needs in this diverse patient population.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What is the current size of epilepsy market by country, and how do we forecast the market will evolve in the coming years?<\/li>\n<li>What key factors will shape the future market, and what drivers and barriers will influence the use of key AEDs? Will the dominance of second-generation therapies continue, and which third-generation therapies will be successful over our forecast period?<\/li>\n<li>How will high-priced third-generation AEDs fare in this highly genericized market?<\/li>\n<li>How have UCB\u2019s Nayzilam and Neurelis\u2019s Valtoco been integrated into the treatment algorithm?<\/li>\n<li>What are the unmet needs in the current epilepsy treatment paradigm? How will emerging therapies address these unmet needs?<\/li>\n<\/ul>\n<p>\u200b<strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><strong>Primary research:<\/strong> Approximately 20 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.<\/p>\n<p><strong>Emerging therapies:<\/strong> Phase II: 12 drugs; Phase III \/ preregistration: 6 drugs.<\/p>\n<p><strong>Market forecast features: <\/strong>Patient-based market forecast extending through 2032, segmented by brands and generics \/ biosimilars.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancement <\/strong>\u200b\u200b\u200b\u200b\u200b\u200b<\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389145","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-epilepsy","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389145\/revisions"}],"predecessor-version":[{"id":576055,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389145\/revisions\/576055"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}